文献速递核素与放射性配体治疗肿瘤 PET/CT

预靶向:放射免疫治疗的未来路径

Pretargeting: A Path Forward for Radioimmunotherapy.
PubMed 文献 · J Nucl Med · 2022-01-01

本文综述预靶向放射免疫诊断与放射免疫治疗的历史、策略与创新,重点涉及生物素-链霉亲和素和半抗原-双特异性单克隆抗体两类蛋白递送系统,以及放射性半抗原和放射性同位素。文章强调肿瘤摄取放大与正常组织暴露降低的优势,并讨论临床转化的挑战与基准。

要点

  • 预靶向将肿瘤靶向步骤与载荷步骤分离,可放大肿瘤摄取并降低正常组织暴露。
  • 关键参数包括抗体免疫原性与特异性、放射性同位素可及性及临床易用性。
  • 各步骤可单独优化,作为模块化系统可广泛适用于不同肿瘤靶点、类型或同位素。

核心结论

  • 预靶向策略在提高肿瘤靶本比和治疗指数方面具有潜力,但临床转化复杂且面临独特挑战。

研究设计与样本

  • 本文为叙述性综述,简要回顾核医学中预靶向策略的起源与发展,重点评估两类蛋白递送系统及放射性半抗原与同位素。

主要发现

  • 预靶向方法将肿瘤靶向步骤与载荷步骤分离,从而放大肿瘤摄取并减少正常组织暴露。
  • 文章重点讨论生物素-链霉亲和素和半抗原-双特异性单克隆抗体两类蛋白递送系统,以及放射性半抗原和放射性同位素。
  • 近期创新包括生物正交化学预靶向和新型蛋白载体(如自组装解组装蛋白和Affibody分子)。

局限性

  • 作者说明本文并非对过去三十年预靶向放射免疫诊断和放射免疫治疗的全面综述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pretargeted radioimmunodiagnosis and radioimmunotherapy aim to efficiently combine antitumor antibodies and medicinal radioisotopes for high-contrast imaging and high-therapeutic-index (TI) tumor targeting, respectively. As opposed to conventional radioimmunoconjugates, pretargeted approaches separate the tumor-targeting step from the payload step, thereby amplifying tumor uptake while reducing normal-tissue exposure. Alongside contrast and TI, critical parameters include antibody immunogenicity and specificity, availability of radioisotopes, and ease of use in the clinic. Each of the steps can be optimized separately; as modular systems, they can find broad applications irrespective of tumor target, tumor type, or radioisotopes. Although this versatility presents enormous opportunity, pretargeting is complex and presents unique challenges for clinical translation and optimal use in patients. The purpose of this article is to provide a brief historical perspective on the origins and development of pretargeting strategies in nuclear medicine, emphasizing 2 protein delivery systems that have been extensively evaluated (i.e., biotin-streptavidin and hapten-bispecific monoclonal antibodies), as well as radiohaptens and radioisotopes. We also highlight recent innovations, including pretargeting with bioorthogonal chemistry and novel protein vectors (such as self-assembling and disassembling proteins and Affibody molecules). We caution the reader that this is by no means a comprehensive review of the past 3 decades of pretargeted radioimmunodiagnosis and pretargeted radioimmunotherapy. But we do aim to highlight major developmental milestones and to identify benchmarks for success with regard to TI and toxicity in preclinical models and clinically. We believe this approach will lead to the identification of key obstacles to clinical success, revive interest in the utility of radiotheranostics applications, and guide development of the next generation of pretargeted theranostics.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cheal SM, Chung SK, Vaughn BA, et al. Pretargeting: A Path Forward for Radioimmunotherapy. J Nucl Med. 2022. PMID: 36215514. doi:10.2967/jnumed.121.262186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。